Artivion (NYSE:AORT) Issues Quarterly Earnings Results

Artivion (NYSE:AORT) released its earnings results on Thursday. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.14, FiscalAI reports. The business had revenue of $123.79 million for the quarter, compared to the consensus estimate of $120.97 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%.

Here are the key takeaways from Artivion’s conference call:

• Third-quarter revenue grew 9% year over year in constant currency, led by 12% growth in stent grafts and 13% growth in On-X valves. Management said On-X supply has improved after manufacturing investments, while acknowledging that adjusted EBITDA fell 8% and gross margin declined.
• Artivion narrowed its 2026 outlook to 8%–10% adjusted constant-currency revenue growth and $93 million–$98 million of adjusted EBITDA. Management cited a Q4 currency headwind and an expected reversal of unusually strong preservation-services revenue; it also forecast PerClot’s departure to reduce 2027 revenue growth by about 2 percentage points and EBITDA growth by 4 points.
• AMDS implants increased following U.S. PMA approval, but starter-set sales remain slow because hospitals face administrative hurdles around the roughly $100,000 upfront purchase. Management said it is working to ease those barriers, but expects account adoption to take time.
• NEXUS preparations are progressing toward a planned U.S. launch on January 1, 2027, with surgeon interest, training, inventory-building, and sales-team expansion underway. Management expects sales to ramp gradually through 2027 and anticipates the combined business will be EBITDA-neutral for the year.
• The ARTIZEN trial for the Arcevo LSA platform has enrolled 56 patients, with enrollment completion expected in mid-2027. Management expects to present initial results from the first 30 patients and, if the trial succeeds, anticipates FDA approval in 2029.

Artivion Price Performance

Shares of NYSE:AORT traded down $5.09 on Friday, hitting $20.23. The company’s stock had a trading volume of 3,246,962 shares, compared to its average volume of 486,118. The company has a 50-day simple moving average of $23.55 and a 200 day simple moving average of $28.98. Artivion has a 1 year low of $19.16 and a 1 year high of $48.25. The company has a market capitalization of $986.66 million, a PE ratio of 43.67 and a beta of 1.31. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51.

Artivion News Summary

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q3 revenue rose 9% year over year to $123.8 million, exceeding analysts’ estimates of about $121 million. The company also reported non-GAAP EPS of $0.08, above a consensus estimate of a $0.06 loss cited in one report. Artivion Q3 results
• Positive Sentiment: Artivion forecast 2026 revenue of $484 million to $492 million and said it is preparing to launch its NEXUS product in January 2027, offering potential future growth catalysts. Revenue outlook and NEXUS launch
• Neutral Sentiment: Citizens JMP lowered its price target to $42 from $48 but maintained a Market Outperform rating; the revised target still implies substantial upside from the cited share price. Citizens JMP recommendations
• Negative Sentiment: Canaccord also cut its target, to $30, adding to concerns about analysts’ reassessment of the stock’s outlook. Canaccord price-target change
• Negative Sentiment: Despite revenue growth, Artivion posted a $7.9 million GAAP net loss, and adjusted EBITDA fell 8% to $22.5 million. Zacks also reported that the $0.08 quarterly EPS missed its $0.11 estimate, highlighting that earnings expectations vary by source and may weigh on sentiment. Zacks earnings analysis

Insiders Place Their Bets

In other news, CEO James Mackin sold 70,000 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the transaction, the chief executive officer directly owned 877,275 shares of the company’s stock, valued at approximately $25,397,111.25. This trade represents a 7.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jean Holloway sold 977 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total value of $27,834.73. Following the completion of the sale, the senior vice president directly owned 184,118 shares in the company, valued at $5,245,521.82. The trade was a 0.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 90,460 shares of company stock valued at $2,557,366 over the last 90 days. Insiders own 6.30% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on AORT. Citigroup reiterated a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Canaccord Genuity Group dropped their price target on Artivion from $40.00 to $30.00 and set a “buy” rating for the company in a research note on Friday. Jefferies Financial Group assumed coverage on Artivion in a report on Tuesday, October 20th. They set a “buy” rating and a $31.00 price objective on the stock. Citizens Jmp reduced their price objective on Artivion from $48.00 to $42.00 and set a “market outperform” rating on the stock in a research report on Friday. Finally, Wall Street Zen cut Artivion from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Artivion has a consensus rating of “Moderate Buy” and a consensus price target of $40.57.

About Artivion

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.